ATRA Investor Pres_JPM 2023_vFINAL.pdf

1、INVESTOR PRESENTATION41STANNUAL J.P.MORGANHEALTHCARE CONFERENCEJANUARY 11,2023Nasdaq:ATRAForward-Looking StatementsThis presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act o

2、f 1995.All statements other than statements of historical facts contained in this presentation,including statements regarding our future results of operations and financial position,future transactions,business strategy,product candidates,correspondence with regulatory authorities,regulatory submiss

3、ions,regulatory approvals,the initiation,timing,progress and results of preclinical studies and clinical trials and our research and development programs,the mechanistic link between EBV and multiple sclerosis and the ability of ATA188 to specifically target such link,ability to sell,manufacture or

4、otherwise commercialize our product and product candidates,research and development costs,timing and likelihood of success,plans and objectives of management for future operations,any royalty payments,our ability to obtain and maintain intellectual property protection for our product and product can

5、didates,and the sufficiency of Ataras cash,cash equivalents,short-term investments to fund its planned operations are forward-looking statements of Atara Biotherapeutics,Inc.(“Atara”or the“Company”).These statements involve known and unknown risks,uncertainties and other important factors that may c

6、ause our actual results,performance or achievements to be materially different from any future results,performance or achievements expressed or implied by the forward-looking statements.In some cases you can identify these statements by forward-looking words such as“believe,”“may,”“will,”“estimate,”